AIT Therapeutics Reports Year End 2017 Financial Results

AIT Therapeutics (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“With the recent financing, we are well funded to achieve our goal of entering the US hospital-based NO market in 2019.  Our vastly superior product, the NO Generator and Delivery System, eliminates the need for high-pressure cylinders, yielding direct benefits to the hospital and allowing pricing flexibility for AIT and our future commercial partner.  The next step prior to submitting the 510(k) is to repeat our commercial design and testing for use with ventilators.  It is important to note that we have already essentially completed our commercial design for our system for use with a mask,” said Mr. Steven Lisi, Chairman and Chief Executive Officer.  “Additionally, our system may revolutionize the treatment of certain respiratory conditions by making at-home treatment with nitric oxide a reality.”

Click here to read the full press release.